Study: Combo therapy cuts death risk from cryptococcal meningitis

04/4/2013 | HealthDay News

A treatment regimen that combines the antifungal drugs amphotericin B and flucytosine can lower cryptococcal meningitis patients' risk of death by 40% compared to amphotericin B alone, a study in the New England Journal of Medicine showed. Survivors also had lower odds of disability if they were treated with flucytosine, the researchers found.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX